UK markets close in 7 hours 50 minutes

Inhibikase Therapeutics, Inc. (IKT)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.0400-0.0500 (-2.39%)
At close: 04:00PM EDT
2.0100 -0.03 (-1.47%)
After hours: 04:37PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.0900
Open2.1000
Bid0.0000 x 0
Ask0.0000 x 0
Day's range2.0200 - 2.1055
52-week range0.7900 - 4.3500
Volume52,727
Avg. volume137,787
Market cap13.396M
Beta (5Y monthly)1.20
PE ratio (TTM)N/A
EPS (TTM)-3.5700
Earnings date13 May 2024 - 17 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est17.50
  • GlobeNewswire

    Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

    BOSTON and ATLANTA, April 18, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today issued a Letter to Shareholders. Dear Fellow Shareholders of Inhibikase Therapeutics: 2024 has been off to a productive start for Inhibikase. Our 2

  • GlobeNewswire

    Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension

    Meeting to discuss potential of IkT-001Pro as a disease modifying treatment for Pulmonary Arterial HypertensionBOSTON and ATLANTA, April 03, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that the Company will meet wi

  • Simply Wall St.

    Inhibikase Therapeutics Full Year 2023 Earnings: EPS Misses Expectations

    Inhibikase Therapeutics ( NASDAQ:IKT ) Full Year 2023 Results Key Financial Results Net loss: US$19.0m (loss widened by...